As the reliance on mobile communication devices increases more and more in daily routines, it seems natural that people will also rely on this communication form when it comes to crisis situations - may it be as a witness, bystander or victim. From the standpoint of First Responders (FRs) and Public Protection and Disaster Relief (PPDR) organizations, it is therefore important, not only to be aware of this development, but also to take measure and develop procedures, guidelines and tools to incorporate (mobile) online communication as an additional information and communication channel. Prof. Dr. Silke Schmidt, Dr. Daniela Knuth and colleagues provide research and guidelines in the textbook "iSAR+ New Media in Crisis Situations".

The human recombinant anti-SARS-CoV-2 antibody COR-101 was developed in close cooperation of Technische Universität Braunschweig, the Helmholtz Centre for Infection Research (HZI) and the biotech company YUMAB GmbH in Braunschweig. The antibody is currently undergoing phase Ib/II clinical trials for the treatment of moderate to severe COVID-19 by CORAT Therapeutics GmbH. The story of the discovery and development of this antibody was now published in the Journal "Cell Reports".

Suicide bombings are causing a rising number of causalties worldwide. These attacks are characterized by the ability of terrorist organizations to detonate high powered explosive devices in proximity to large groups of civilians. The devastating effects of heavy shrapnel and blast wave combine to cause a wide array of injuries. Severe injury to gas-containing organs is common, multiple entry sites are frequent, and severe soft tissue damage is widespread. Thoracic, abdominal and pelvis-traversing missiles are not uncommon among survivors. Triage and initial evaluation are essential in these chaotic scenarios. Israeli experts in all fields of medicine provide pragmatic knowledge, how to treat and manage the victims: The textbook "Terror and Medicine" is based and focused on practical experience.

Many organ transplantations fail due Covid-19-infection. S. Yin and colleagues (Chengdu/China) evaluated 59 studies with 7071 Covid-19-positive patients and presented the results during the current American Transplant Congress (virtual):